Immunome

Immunome

Biotechnology, 665 Stockton Dr, EXTON, Pennsylvania, 19341, United States, 11-50 Employees

immunome.com

  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is IMMUNOME

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages m...

Read More

map
  • 665 Stockton Dr, EXTON, Pennsylvania, 19341, United States Headquarters: 665 Stockton Dr, EXTON, Pennsylvania, 19341, United States
  • 2008 Date Founded: 2008
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from IMMUNOME

Immunome Org Chart and Mapping

Employees

Sandra Stoneman

Chief Legal Officer and General Counsel

Justin Marraffa

Senior Financial Accountant

Lei Cochran

Sr. Director, Discovery Program Management & Alliance Management

Ben Harman

Senior Director, Target Id & Validation

Kaili Chickering

Senior Lab and Facilities Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Immunome

Answer: Immunome's headquarters are located at 665 Stockton Dr, EXTON, Pennsylvania, 19341, United States

Answer: Immunome's phone number is 61********

Answer: Immunome's official website is https://immunome.com

Answer: Immunome's revenue is $10 Million to $25 Million

Answer: Immunome's SIC: 2834

Answer: Immunome has 11-50 employees

Answer: Immunome is in Biotechnology

Answer: Immunome contact info: Phone number: 61******** Website: https://immunome.com

Answer: Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages most highly educated immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access